About Nouscom
Nouscom is a private clinical-stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens. Its proprietary platform uses recombinant viral vectors to induce anti-tumor T cell responses, with clinical programs including NOUS-209 for MSI-H colorectal cancer and NOUS-PEV for personalized cancer immunotherapy. The company serves the oncology/biotech sector and has licensed one program to Janssen Oncology.
Company details
Funding
Total raised
$152M
Last stage
Series C
Investors
Founders
Riccardo Cortese
Italian scientist and entrepreneur; founder of genetic vaccine company Okairos (acquired by GSK in 2013) and co-founder of Nouscom in 2015. Passed away in April 2017.
Alfredo Nicosia
Co-founder and former CEO of Nouscom; previously CSO and co-founder of Okairos. Led preclinical and clinical development of vaccines and monoclonal antibodies.
Cinzia Traboni
Co-founder of Nouscom; previously Head of Regulatory Affairs at Okairos, supporting clinical trials in cancer immunotherapy in the US and EU.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.